A Phase 2b/3, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease (OASIS-1)
Latest Information Update: 21 Mar 2023
Price :
$35 *
At a glance
- Drugs ALY 688 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Acronyms OASIS-1
- Sponsors Allysta Pharmaceuticals
- 14 Mar 2023 Status changed from active, no longer recruiting to completed.
- 08 Nov 2022 Planned End Date changed from 1 Mar 2022 to 1 Feb 2023.
- 08 Nov 2022 Planned primary completion date changed from 1 Mar 2022 to 1 Feb 2023.